Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celevis is a topical medical device developed by the Italian pharmaceutical company Giuliani, specifically formulated as a gel for the management of proctological conditions such as anal fissures and hemorrhoids. The product functions primarily by creating a protective mechanical barrier over the anal mucosa, which shields the affected tissue from external irritants and reduces symptoms like pain, itching, and burning. Its key component is typically hyaluronic acid (sodium hyaluronate), which provides essential hydration and supports the natural healing and repair processes of the mucosal lining. Celevis is marketed as a non-pharmacological treatment option for patients seeking relief from the discomfort associated with anorectal disorders and is part of Giuliani's gastrointestinal and proctological portfolio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Celevis.